Background and Purpose-Individuals with human immunodeficiency virus (HIV) who use highly active antiretroviral therapy (HAART) may have an increased risk for cardiovascular-related events, although the underlying mechanism remains unclear. We tested the hypothesis that carotid arterial stiffness was higher among persons using HAART compared to HAART-naïve and HIV-uninfected persons. Methods-Between 2004 and 2006, we performed high-resolution B-mode ultrasound on 2789 HIV-infected and HIV-uninfected participants of the Women's Interagency HIV Study (1865 women) and the Multicenter AIDS Cohort Study (924 men) and determined carotid arterial distensibility, which is a direct measure of carotid arterial stiffness. We used generalized estimating equations to evaluate the association between distensibility and HIV infection, CD4 ϩ cell count, and exposure to HAART adjusted for demographic, behavioral, and clinical characteristics. Results-In multivariable analysis, distensibility was 4.3% lower (95% confidence interval, Ϫ7.4% to Ϫ1.1%) among HIV-infected vs uninfected participants. Among HIV-infected participants with Ͻ200 CD4 ϩ cells, distensibility was 10.5% lower (95% confidence interval, Ϫ14.5% to Ϫ6.2%) than that among HIV-uninfected participants, and this effect did not differ significantly by cohort or race. Concurrent HAART use was independently associated with lower distensibility among Multicenter AIDS Cohort Study participants but not among Women's Interagency HIV Study participants. Conclusions-Our finding that advanced HIV-related immunosuppression was associated with increased carotid arterial stiffness independent from the effects of traditional atherosclerosis risk factors suggests that the etiologic mechanism underlying reports of an increased cardiovascular disease risk among HIV-infected individuals might involve HIV-related immunosuppression leading to vascular dysfunction and arterial stiffening. (Stroke.
T he benefits of highly active antiretroviral therapy (HAART) for treating human immunodeficiency virus (HIV) infection are well-established, 1,2 but there is mounting evidence that HAART may also be linked to an increased risk of cardiovascular disease. Protease inhibitor (PI)-based HAART appears to be associated with an increased risk of myocardial infarction, 3 perhaps from increased levels of atherosclerosis. 4 Several risk factors for atherosclerosis, including hyperglycemia, diabetes, hypertension, and dyslipidemia, have been reported to be more common in persons with HIV, especially among those using PI-containing HAART regimens. 4 -8 However, the relationship of HIV and HAART with cardiovascular disease is not clear. Data from the Strategies for Management of Antiretroviral Therapy trial suggest that in comparison to patients with HIV managed using a drug conservation strategy, those receiving uninterrupted antiretroviral treatment had a lower risk of vascular events despite their sustained exposure to HAART. 9 Furthermore, a large cohort study recently found that HIV and HAART were not associated with an increased rate of cardiovascular events, 10 and carotid intima-media thickness has not been consistently found to be associated with HIV infection or HAART use. 11, 12 We previously reported that systolic hypertension, but not diastolic hypertension, was increased with longer HAART exposure. 13 These findings suggest that the vascular effect of HAART may involve the "sclerosis" component of atherosclerosis that is measured by the stiffness of the arteries, 14 which, itself, is only weakly correlated with carotid intimamedia thickness 15 and can predict cardiovascular events and death. 16 The current study of Ͼ2700 men and women was designed to investigate the association of HIV infection and HAART use with arterial stiffness using measurements of common carotid artery diameter change over the cardiac cycle.
Subjects and Methods

Study Population
This cross-sectional study included baseline data from HIV-infected and HIV-uninfected participants enrolled in the Carotid Ultrasound Substudy of the Multicenter AIDS Cohort Study (MACS) and the Women's Interagency HIV Cohort Study (WIHS). MACS and WIHS are ongoing observational HIV cohort studies comprising 6972 men and 3766 women, respectively, in selected metropolitan areas across the United States. Recruitment and follow-up procedures have been reported previously. [17] [18] [19] [20] Between April 2004 and March 2006, 1865 women and 924 men underwent a baseline carotid ultrasound examination. 21 Briefly, all WIHS participants who attended a study visit during this time period were eligible for this substudy, whereas MACS participants attending a study visit during this calendar period were eligible if they were at least 40 years old, weighed Ͻ300 pounds, and had no history of cardiovascular disease. Among WIHS participants, 84 (4.5%) reported a history of myocardial infarction, congestive heart failure, or stroke. All participants gave written informed consent before enrollment, and this study was approved by the Institutional Review Boards at each of the MACS and WIHS institutions.
Study Outcome: Carotid Arterial Distensibility
High-resolution B-mode ultrasound was used to image the right common carotid artery, internal carotid artery, and carotid bulb as previously described. 22 Sonographers at each of the WIHS and MACS sites were trained at the University of Southern California Atherosclerosis Research Unit Core Imaging and Reading Center, and all scans were centrally read at the Core Imaging and Reading Center. The ultrasound assessment included measurements of the right common carotid artery diameter at systole (D S ) and diastole (D D ), and pulse pressure (PP) was measured at the brachial artery. Using these measurements, we quantified carotid artery stiffness using the following index of carotid distensibility:
where lower values reflect a stiffer carotid artery. Distensibility was standardized to the units reported by Lage et al 23 (10 Ϫ6 ϫ Newtons Ϫ1 ϫ meters 2 ).
Exposure Variables
HIV infection was determined via serological testing on specimens obtained at each MACS or WIHS study visit using enzyme-linked immunosorbent assays and confirmed using Western blot assays. 17 
Statistical Analysis
We characterized the study population using graphical displays of the data and descriptive statistics (eg, median, interquartile range), and the characteristics of the MACS and WIHS cohorts were compared using a 2 test of association. All statistical comparisons of distensibility were performed using generalized estimating equations 25 to account for clustering within the 10 MACS and WIHS sites. Multiple regression analyses were performed for the entire study population and then separately for the MACS and WIHS cohorts. Distensibility was natural log-transformed to account for its skewed distribution, and the model results are reported as the percent difference (PD) in distensibility between those with and those without the corresponding covariate. Although Ϸ90% of participants had complete data for all study variables other than fasting glucose, we used multiple imputation 26 to account for missing data in the multiple regression models. Statistical significance was defined as a 2-sided PϽ0.05. All statistical analyses were performed using SAS 9.2 (SAS Institute).
Results
The characteristics of the 2789 study participants are shown in Table 1 ; two-thirds were from the WIHS, the median age was 44.3 years (range, 20.2-83.0), and 48% were black. More than one-half of the participants were overweight or obese (BMI Ͼ25), 21% had LDL-c Ͼ3.38 mmol/L (130 mg/dL), 30% had HDL-c Ͻ1.04 mmol/L (40 mg/dL), and 11% had systolic blood pressure Ͼ140 mm Hg. Diabetes mellitus was documented in 16% of participants, but only 5% of those who were fasting at the time of the study visit had a fasting glucose level Ͼ6.94 mmol/L (125 mg/dL). Approximately two-thirds (69%) of participants were infected with HIV, among whom 13% had a CD4 ϩ cell count Ͻ200 (cells/mL) and 70% were using HAART at the time of the ultrasound examination.
In addition to the gender difference between the MACS and WIHS cohorts, the distributions of all other characteristics included in Table 1 differed significantly between the cohorts except diabetes, fasting glucose, and the duration of HAART exposure among those who were using HAART at the time of the examination. Compared to HIV-uninfected participants, those infected with HIV were significantly less likely to have education beyond high school, more likely to have a history of injection drug use, more likely to have a family history of myocardial infarction, and had significantly lower BMI, LDL-c, and systolic blood pressure levels (data not shown).
Overall, the median carotid distensibility was 16.8ϫ10 Ϫ6 N Ϫ1 m 2 , and the relationship between distensibility and age was similar in the 2 cohorts ( Figure) . In univariate analyses, distensibility was significantly associated with age, race/ethnicity, history of injection drug use, family history of myocardial infarction, and all the clinical characteristics included in Table 1 . Distensibility was also significantly lower among persons infected with HIV and among current HAART users who had initiated HAART Ͼ5 years earlier.
HIV infection remained significantly associated with lower distensibility (PD, Ϫ4.3; 95% CI, Ϫ7.4 to Ϫ1.1) in the multiple regression analysis ( Table 2 ). The effect of HIV was greater in the MACS (PD, Ϫ5.5) than in the WIHS (PD, Ϫ1.9), but the difference between the cohorts was not statistically significant (P value for interactionϭ0.24). Other characteristics that were independently 
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associated with lower distensibility in this model were older age, black and Hispanic race/ethnicity, higher BMI, higher LDL-c, lower HDL-c, and higher systolic blood pressure. We then added covariates for the use of blood pressure medications and cholesterol-lowering medications to the regression models, but these cofactors were not independently associated with distensibility (data not shown) and their inclusion did not alter any inferences taken from the results in Table 2 .
To examine the association between HIV-related immunosuppression and distensibility, we stratified the HIV-infected subgroup by CD4 ϩ cell count. HIV-infected participants with Ͻ200 CD4 ϩ cells had significantly less distensible carotid arteries (PD, Ϫ10.5; 95% CI, Ϫ14.5 to Ϫ6.2; (Table 3 , model 1) compared to those who were not infected with HIV, and the association between advanced HIV-related immunosuppression and distensibility did not differ significantly between MACS (PD, Ϫ6.9) and WIHS (PD, Ϫ9.2; P for interactionϭ0.46) or between blacks (PD, Ϫ9.9) and nonblacks (PD, Ϫ9.5; P for interactionϭ0.42).
Among the 1931 HIV-infected participants, distensibility was significantly lower among those using HAART in the MACS (PD, Ϫ4.2; 95% CI, Ϫ7.0 to Ϫ1.4), but not in the WIHS or in the overall model (Table 3 , model 2). Among the 1317 HAART users, distensibility was also significantly lower in MACS participants who had been using HAART for Ͼ5 years (PD, Ϫ4.6; 95% CI, Ϫ8.5 to Ϫ0.6), but duration of HAART use was not significantly associated with distensibility in the WIHS or overall models (Table 3 , model 3). Finally, distensibility was similar among participants using PI-based and not PIbased HAART regimens (Table 3 , model 4). 
Discussion
In this study, the largest study of the association between HIV disease and arterial stiffness performed to date to our knowledge, carotid arterial distensibility was significantly lower in HIV-infected vs HIV-uninfected participants after adjusting for the demographic, behavioral, and clinical characteristics of the study population. Distensibility was lowest among HIV-infected participants with advanced HIV-related immunosuppression, and this was true for both MACS and WIHS participants and for both blacks and non-blacks. Distensibility was also significantly lower among HIV-infected HAART users in MACS, especially among men who had initiated HAART Ͼ5 years earlier, but it was not associated with HAART use in the WIHS, nor did it differ between those using PI-containing HAART vs HAART without a PI in either cohort. Thus, our study provides stronger support for an effect of HIV-related immunosuppression, compared to that of HAART, on carotid distensiblity.
Much of the research linking HIV disease with cardiovascular disease has focused on the effects of HIV therapy on metabolic-related factors such as hyperglycemia, insulin resistance, dyslipidemia, and fat redistribution, which contribute to arterial disease 8, 27, 28 and may account for some of the increased risk of cardiovascular disease observed among HIV-infected persons using HAART. 4, 29, 30 However, if these factors were to mediate the association between HIV disease and atherosclerosis, then we would have expected that adjusting for them would nullify the association between HIV and distensibility in our analysis; this was not the case. Moreover, BMI, LDL-c, HDL-c, and systolic blood pressure were all independently associated with distensibility in the expected direction, which supports the validity of our results.
Arterial stiffness is associated with impaired endothelial function, 31 and it has been proposed that HIV may affect the vasculature directly via endothelial damage, 32 promoting arterial stiffness [33] [34] [35] and contributing to atherogenesis. 36 Consistent with this hypothesis, HIV infection was associated 
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with increased arterial stiffness among children. 37 The AIDS Clinical Trials Group Study 5152s reported that initiating antiretroviral treatment improves endothelial reactivity, with a direct correlation between the improvement in vascular function and the viral and immunologic response to therapy. 38 Data from the Strategies for Management of Antiretroviral Therapy trial suggest that, in terms of vascular disease, the risks associated with occasional adverse metabolic effects of antiretroviral therapies may be outweighed by the benefits of maintaining good immunologic function. 9 A previous study from our group found that advanced HIV-related immunosuppression was independently associated with an increased prevalence of carotid lesions but not with carotid intimamedia thickness. 21 Together with our results, these findings suggest that the etiologic pathway connecting HIV infection to arterial stiffness may directly involve HIV-related immunosuppression rather than, or in addition to, antiretroviral therapy and atherosclerosis risk factors. However, caution is urged when interpreting our data because CD4 ϩ cell count was a marker of the immunologic status at the time of the ultrasound evaluation, whereas arterial stiffness may stem from multiple processes operating over many years. 39 Our finding that HAART was associated with increased carotid artery stiffness in the MACS and that stiffness increased with prolonged HAART use is consistent with our previous MACS study 13 in which men who had prolonged exposure to HAART had a higher prevalence of systolic hypertension. It is unclear, however, why this association existed only among the MACS participants in the current study. Although the effect of antiretroviral therapies on the vasculature might differ between men and women, it is also possible that differences in the course or treatment of HIV infection between the MACS and WIHS cohorts or, more generally, between men and women 40 may have led to these results. Nevertheless, in comparison to HIV-related immunosuppression, HAART was not as strongly or as consistently associated with increased carotid stiffness.
The strengths of the current study include the large sample size, being nested within 2 ongoing HIV cohorts, and the analysis of standardized data from 10 different sites. The primary limitation of our study was its cross-sectional design that made it impossible for us to tease apart the etiologic importance of HIV-related immunosuppression vs therapy, to describe changes in arterial stiffness across time, or to evaluate the effect of increased stiffness on cardiovascular outcomes. Finally, the unique demographic and clinical characteristics of the MACS and WIHS participants must be considered when interpreting the results from this study.
Conclusion
HIV-related immunosuppression was associated with increased carotid stiffness among both MACS and WIHS participants, whereas HAART use was associated with carotid stiffness among the MACS participants only. The mechanisms underlying these findings remain unknown, but these results suggest that the etiologic pathways may be independent from traditional atherosclerosis risk factors. Our study contributes to a growing volume of research supporting the hypothesis that HIV-related immunosuppression impacts the risk of cardiovascular disease and underscores the need for further exploration of cardiovascular disease risk among persons infected with HIV.
